Compositions and methods relating to the treatment of diseases
The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role, such as inflammatory responses and autoimmune diseases. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.
1. A method for enhancing a Th 1 1-mediated immune response and suppressing a Th2/Th17-mediated immune response in a subject, said method comprising the step of:
(i) administering to the subject a therapeutically effective amount of a IFN-α 10 -IFN-α 14 hybrid, wherein the IFN-α 10 -IFN-α 14 hybrid comprises the amino acid sequence set forth by SEQ ID NO: 1 .
2. The method as claimed in claim 1 , wherein the subject suffers from a condition selected from the group consisting of: an autoimmune disease, an inflammatory disease, an allergy, an allergic disease, and a cancer.
3. The method as claimed in claim 2 , wherein the inflammatory disease is inflammatory bowel disease, ulcerative colitis, or Crohn's disease.
4. The method as claimed in claim 2 , wherein the allergy or the allergic disease is a food allergy.
5. The method as claimed in claim 2 , wherein the method further comprises administering to the subject a therapeutically effective amount of a vaccine composition for treatment of the condition.
6. The method as claimed in claim 5 , wherein the vaccine composition comprises at least one allergen capable of mediating a Th2/Th17 immune response, a food allergen capable of mediating a Th2/Th17 immune response, or a tumour antigen capable of mediating a Th2/Th17 immune response.
7. The method as claimed in claim 1 , wherein the IFN-α 10 -IFN-α 14 hybrid has improved binding to interferon receptor 1 and interferon receptor 2 in comparison to IFN-α 10 or IFN-α 14 .
8. A method for suppressing IL- 17 expression in a subject having a condition mediated by enhanced expression of IL- 17 , said method comprising the step of:
(i) administering to the subject a therapeutically effective amount of a IFN-α 10 -IFN-α 14 hybrid, wherein the IFN-α 10 -IFN-α 14 hybrid comprises the amino acid sequence set forth by SEQ ID NO: 1 .
9. The method as claimed in claim 8 , wherein the IFN-α 10 -IFN-α 14 hybrid has improved binding to interferon receptor 1 and interferon receptor 2 in comparison to IFN-α 10 or IFN-α 14 .
10. The method of claim 6 , wherein the tumour antigen is a tumour specific antigen or tumour-associated antigen.
11. The method as claimed in claim 2 , wherein the cancer is hepatic cell cancer, lung cancer, non-small cell lung cancer, ovarian cancer, breast cancer, skin cancer, melanoma, genitourinary cancer, prostate cancer, renal cell cancer, or bladder cancer.
12. The method of claim 2 , wherein the allergy is selected from the group consisting of: a food allergy, an environmental allergy, Heiner syndrome, oral allergy syndrome, eosinophilic gastroenteritis, IgE mediated gastrointestinal food allergy, and C1 esterase deficiency.